Recent Antiemetics Clinical Trials

Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Botteman M, Nickel K, Corman S, Turini M, Binder G. Support Care Cancer. 2019. Jun 3. doi: 10.1007/s00520-019-04824-y. [Epub ahead of print]

Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study. Harder S, Groenvold M, Isaksen J, Sigaard J, Frandsen KB, Neergaard MA, Mondrup L, Herrstedt J. Support Care Cancer. 2019 Aug;27(8):2849-2856.

Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial. Herrstedt J, Summers Y, Jordan K, von Pawel J, Jakobsen AH, Ewertz M, Chan S, Naik JD, Karthaus M, Dubey S, Davis R, Fox GM. Support Care Cancer. 2019 Jul;27(7):2699-2705.

Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study. Araz M, Karaagac M, Korkmaz L, Koral L, Inci F, Beypinar I, Uysal M, Artac M. Cancer Chemother Pharmacol. 2019 Jun;83(6):1091-1097.

One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. Okada Y, Oba K, Furukawa N, Kosaka Y, Okita K, Yuki S, Komatsu Y, Celio L, Aapro M. Oncologist. 2019 Jun 19. pii: theoncologist.2019-0133.

Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan. Kashiwa M, Matsushita R. Clin Ther. 2019 May;41(5):929-942.

Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial. Chaudhary NK, John RR, Boddu D, Mahasampath G, Nesadeepam N, Mathew LG. J Pediatr Hematol Oncol. 2019 May;41(4):294-297.

Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies. Schwartzberg L, Karthaus M, Rossi G, Rizzi G, Borroni ME, Rugo HS, Jordan K, Hansen V. Cancer Med. 2019 May;8(5):2064-2073. doi: 10.1002/cam4.2091.

A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy. Osaki A, Inoue K, Sakai H, Yamada K, Minato K, Ohyanagi F, Tokuda Y, Ikeda N, Kagamu H, Kubota K, Tamura T, Saeki T. Jpn J Clin Oncol. 2019 Feb 1;49(2):121-129.

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study. Jeon SY, Han HS, Bae WK, Park MR, Shim H, Lee SC, Go SI, Yun HJ, Im YJ, Song EK. Cancer Res Treat. 2019 Jan;51(1):90-97.

Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study. Harder S, Groenvold M, Isaksen J, Sigaard J, Frandsen KB, Neergaard MA, Mondrup L, Herrstedt J. Support Care Cancer. 2018 Dec 14. doi: 10.1007/s00520-018-4593-3.

Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer. Wu F, Lin X, Yang Z, Sun Z, Zeng F, Heng J, Qu J, Zeng L, Yang N, Zhang Y. Clin Lung Cancer. 2018 Nov;19(6):e913-e918.

Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Yokoe T, Hayashida T, Nagayama A, Nakashoji A, Maeda H, Seki T, Takahashi M, Takano T, Abe T, Kitagawa Y. Oncologist. 2018 Oct 17. pii: theoncologist.2018-0140.

Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial. Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D. Biol Blood Marrow Transplant. 2018 Oct;24(10):2065-2071.

Low-dose dexamethasone with fosaprepitant and palonosetron to prevent cisplatin-induced nausea and vomiting in head and neck cancer patients. Kono T, Ueda T, Takumida M, Furuie H, Hamamoto T, Takeno S, Hirakawa K. Acta Otolaryngol. 2018 Oct;138(10):921-925.

Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Sutherland A, Naessens K, Plugge E, Ware L, Head K, Burton MJ, Wee B. Cochrane Database Syst Rev. 2018 Sep 21;9:CD01255.

Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131). Nishio S, Aihara S, Shimokawa M, Fujishita A, Taniguchi S, Hachisuga T, Yanazume S, Kobayashi H, Murakami F, Numa F, Kotera K, Okura N, Toki N, Yokoyama M, Ushijima K. J Gynecol Oncol. 2018 Sep;29(5):e77.

A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy. Jain S, Kapoor G, Koneru S, Vishwakarma G. Support Care Cancer. 2018 Sep;26(9):3091-3097.

A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT). Bubalo J, Mulverhill K, Meyers G, Hayes-Lattin B, Maziarz R. Bone Marrow Transplant. 2018 Aug;53(8):1010-1018.

Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy. Bošnjak SM, Stamatovic L, Borroni ME, Rizzi G, Jordan K. Int J Gynecol Cancer. 2018 Jul;28(6):1153-1161.

A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. Hardy J, Skerman H, Glare P, Philip J, Hudson P, Mitchell G, Martin P, Spruyt O, Currow D, Yates P. BMC Cancer. 2018 May 2;18(1):510. doi: 10.1186/s12885-018-4404-8.

Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy. Ioroi T, Furukawa J, Kume M, Hirata S, Utsubo Y, Mizuta N, Miyake H, Fujisawa M, Hirai M. Support Care Cancer. 2018 May;26(5):1419-1423.

Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. Bubalo JS, Herrington JD, Takemoto M, Willman P, Edwards MS, Williams C, Fisher A, Palumbo A, Chen E, Blanke C, Lopez CD. Support Care Cancer. 2018 Apr;26(4):1273-1279.

Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Chow R, Tsao M, Chiu L, Popovic M, Milakovic M, Lam H, DeAngelis C. Ann Palliat Med. 2018 Apr;7(2):221-233.

A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N. Int J Clin Oncol. 2018 Apr;23(2):382-388.

Comparative efficacy and tolerability of antiemetic prophylaxis for adult highly emetogenic chemotherapy: A network meta-analysis of 143 randomized controlled trials. Cheng J, Cai M, Shuai X, Gao J, Wang G, Tao K. Int J Cancer. 2018 Mar 1;142(5):1067-1076.

Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial. Tsukuura H, Miyazaki M, Morita T, Sugishita M, Kato H, Murasaki Y, Gyawali B, Kubo Y, Ando M, Kondo M, Yamada K, Hasegawa Y, Ando Y. Oncologist. 2018 Mar;23(3):367-374.

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, Chessari S, Lanzarotti C, Jordan K, Aapro M. Ann Oncol. 2018 Feb 1;29(2):452-458.

Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. Bun S, Yonemori K, Akagi T, Noguchi E, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Makino Y, Hayashi Y, Tamura K. Invest New Drugs. 2018 Feb;36(1):151-155.

A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy. Takahashi T, Okada T, Ikejiri F, Ito S, Okada Y, Takahashi F, Kumanomido S, Jo Y, Adachi K, Onishi C, Kawakami K, Miyake T, Inoue M, Suzuki R, Suzumiya J. Int J Clin Oncol. 2018 Feb;23(1):189-194.

Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study. Flank J, Schechter T, Gibson P, Johnston DL, Orsey AD, Portwine C, Sung L, Dupuis LL. Support Care Cancer. 2018 Feb;26(2):549-555.

Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy. Tan J, Wang S, Liang X, Li CC, Zhang J, Zhao Z, Kong XR, Deng X, Peng L, Yang C. Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.2681.

Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting. Uchida M, Nakamura T, Hata K, Watanabe H, Mori Y, Kato K, Kamezaki K, Takenaka K, Shiratsuchi M, Hosohata K, Miyamoto T, Akashi K. J Pharm Health Care Sci. 2018 Jan 9;4:1.

Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study. Herrstedt J, Summers Y, Daugaard G, Christensen TB, Holmskov K, Taylor PD, Fox GM, Molassiotis A. Support Care Cancer. 2018 Jan;26(1):139-145.

Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin's lymphoma patients undergoing repeated cycles of the CHOP regimen. Saito B, Nakashima H, Abe M, Murai S, Baba Y, Arai N, Kawaguchi Y, Fujiwara S, Kabasawa N, Tsukamoto H, Uto Y, Ariizumi H, Yanagisawa K, Hattori N, Harada H, Nakamaki T. Support Care Cancer. 2018 Jan;26(1):269-274.

Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients. Sento S, Kitamura N, Yamamoto T, Nakashiro K, Hamakawa H, Ibaragi S, Sasaki A, Takamaru N, Miyamoto Y, Kodani I, Ryoke K, Mishima K, Ueyama Y; ORAL CANCER STUDY GROUP OF CHUGOKU-SHIKOKU. Anticancer Res. 2017 Dec;37(12):6977-6981.

Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study). Zhang L, Qu X, Teng Y, Shi J, Yu P, Sun T, Wang J, Zhu Z, Zhang X, Zhao M, Liu J, Jin B, Luo Y, Teng Z, Dong Y, Wen F, An Y, Yuan C, Chen T, Zhou L, Chen Y, Zhang J, Wang Z, Qu J, Jin F, Zhang J, Jin X, Xie X, Wang J, Man L, Fu L, Liu Y. J Clin Oncol. 2017 Nov 1;35(31):3558-3565. doi: 10.1200/JCO.2017.72.2538.

Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study. Yang LQ, Sun XC, Qin SK, Cheng Y, Shi JH, Chen ZD, Wang QM, Zhang HL, Hu B, Liu B, Zhang QY, Wu Q, Wang D, Shu YQ, Dong J, Han BH, Wang KM, Dang CX, Li JL, Wang HB, Li BL, Lu JG, Zhang ZH, Chen YX. Eur J Cancer Care (Engl). 2017 Nov;26(6).

A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. Nakashima K, Murakami H, Yokoyama K, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Nishiyama F, Kikugawa M, Kaneko M, Iwamoto Y, Koizumi S, Mori K, Isobe T, Takahashi T. Jpn J Clin Oncol. 2017 Sep 1;47(9):840-843.

A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer. Sugimori Y, Ota T, Ujihira T, Ishiguro T, Ogishima D. J Obstet Gynaecol Res. 2017 Sep;43(9):1454-1459. 

Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). Vayne-Bossert P, Haywood A, Good P, Khan S, Rickett K, Hardy JR. Cochrane Database Syst Rev. 2017 Jul 3;7:CD012002.

Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis. Yang T, Liu Q, Lu M, Ma L, Zhou Y, Cui Y. Br J Clin Pharmacol. 2017 Jul;83(7):1369-1379.

Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breastcancer patients: A subanalysis from two phase III trials. Rugo HS, Rossi G, Rizzi G, Aapro M. Breast. 2017 Jun;33:76-82.

Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study. Ito F, Furukawa N. Support Care Cancer. 2017 Jun;25(6):1941-1945.

Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Inoue T, Kimura M, Uchida J, Nishino K, Kumagai T, Taniguchi J, Imamura F. Int J Clin Oncol. 2017 Jun;22(3):600-604.

Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT). Ades S, Halyard M, Wilson K, Ashikaga T, Heimann R, Kumar S, Blackstock W. Support Care Cancer. 2017 May;25(5):1503-1510.

Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials. Okumura LM, D'Athayde Rodrigues F, Ferreira MAP, Moreira LB. Br J Clin Pharmacol. 2017 May;83(5):1108-1117

Prophylaxis of radiation-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Li WS, van der Velden JM, Ganesh V, Vuong S, Raman S, Popovic M, Lam H, Wong KH, Ngan RK, Burbach JPM, DeAngelis C, Xxxx RM, Chow E. Ann Palliat Med. 2017 Apr;6(2):104-117.

Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study. Isoda A, Saito R, Komatsu F, Negishi Y, Oosawa N, Ishikawa T, Miyazawa Y, Matsumoto M, Sawamura M, Manaka A. Int J Hematol. 2017 Apr;105(4):478-484.

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Aapro M, Karthaus M, Schwartzberg L, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Hansen V, Rossi G, Rizzi G, Borroni ME, Rugo H. Support Care Cancer. 2017 Apr;25(4):1127-1135.

Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Kim JE, Jang JS, Kim JW, Sung YL, Cho CH, Lee MA, Kim DJ, Ahn MJ, Lee KY, Sym SJ, Lim MC, Jung H, Cho EK, Min KW. Support Care Cancer. 2017 Mar;25(3):801-809.

A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Nakagaki M, Barras M, Curley C, Butler JP, Kennedy GA. Support Care Cancer. 2017 Feb;25(2):607-613.

Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study. Yang LQ, Sun XC, Qin SK, Chen YX, Zhang HL, Cheng Y, Chen ZD, Shi JH, Wu Q, Bai YX, Han BH, Liu W, Ouyang XN, Liu JW, Zhang ZH, Li YQ, Xu JM, Yu SY. Chin Clin Oncol. 2016 Dec;5(6):79.